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ABSTRACT 
BACKGROUND: Graves’ disease is routinely treated with antithyroid drugs (ATD), 
radioactive-iodine (RAI), or surgery but it is uncertain whether the choice of initial 
therapy influences long-term outcomes. We evaluated cardiovascular morbidity and 
mortality according to the modality and effectiveness of primary therapy in Graves’ 
disease. 
METHODS: The study was conducted through linked datasets within the All-Wales 
Secure Anonymised Information Linkage (SAIL) Databank. Graves’ disease patients 
were identified from a regional TSH-receptor-antibody test register, (n=4,189, female 
82%, 1998–2013) and matched by age and sex to a control population in SAIL 
(n=16,756). Patients were grouped by treatment within one-year of diagnosis as: (1) 
ATD (n=3587), (2) RAI with resolved hyperthyroidism (RAI-Group-A, n=250), and (3) 
RAI with unresolved hyperthyroidism (RAI-Group-B, n=182). One-year landmark 
Kaplan-Meier and Cox regression models were used to analyse the association of 
treatment with all-cause mortality and major adverse cardiovascular events (MACE, 
myocardial infarction, heart failure, ischaemic stroke, or death). The relationship 
between FT4 concentration and outcomes was analysed using restricted cubic-spline 
regression models. 
FINDINGS:  Overall, patients had increased mortality compared to controls (HR 1·23, 
95%CI 1·06, 1·42). Compared to ATD-treated patients, mortality was reduced in RAI-
Group-A (HR 0·50, 95%CI 0·29, 0·85) but not RAI-Group-B (HR 1·51, 95%CI 0·96, 
2·37). Persistently low-TSH at 1-year was associated with increased mortality 
independent of treatment modality (HR 1·55, 95%CI 1·08-2·24). Spline-regressions 
demonstrated a positive non-linear relationship between 1-year-FT4 and outcomes. 
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INTERPRETATION:  Regardless of therapy modality, early and effective control of 
Graves’ hyperthyroidism is associated with improved survival compared to less 
effective control.  
FUNDING: National Institute for Social Care and Health Research (NISCHR), Wales 
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RESEARCH IN CONTEXT  
Evidence before this study 
We searched PubMed for articles published up to October 2018, without language 
restrictions, that addressed mortality outcomes in relation to treatment modality in 
patients with hyperthyroidism. Our search terms were (“hyperthyroidism” OR 
“thyrotoxicosis” OR “Graves’ disease”) AND (“mortality” OR “survival”) AND 
(“treatment” OR “antithyroid drugs” OR “thionamides” OR “radioactive iodine” OR 
“thyroidectomy”). Although several studies reported excess mortality in radioiodine-
treated cohorts, these studies did not include patients treated with antithyroid drugs 
which currently represents the predominant therapy modality for Graves’ disease 
worldwide. Only one study to date has compared hyperthyroidism mortality according 
to treatment with antithyroid drugs or radioiodine. This study showed survival 
advantages following radioiodine-induced hypothyroidism compared to during 
antithyroid drug treatment. However, the study comprised a heterogeneous 
hyperthyroid cohort that was underpowered to show treatment effects in the Graves’ 
disease subset of 345 patients. 
Added value of this study 
To the best of our knowledge ours is the first study to show that early and complete 
resolution of hyperthyroidism in patients with Graves’ disease is associated with 
improved survival compared to less effective control. We show that survival in patients 
with Graves’ disease is associated with the rapid restoration of normal thyroid status 
rather than therapy modality per se. Using flexible spline regression modelling we 
demonstrate a positive association between FT4 levels after initial therapy and 
subsequent cardiovascular morbidity and mortality.  
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Implications of all the available evidence 
Our findings emphasise the importance of prompt elimination of hyperthyroidism and 
maintenance of normal thyroid status in the care of Graves’ disease patients. The 
choice of therapy should be driven by the prospects of successful resolution of 
hyperthyroidism and therefore, early definitive therapy should be offered to patients 
unlikely to achieve remission with antithyroid drugs alone. 
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INTRODUCTION 
Graves’ disease is the most common cause of hyperthyroidism in iodine-sufficient 
countries, affecting 0·5–1.0% of the population1,2. Hyperthyroidism in Graves’ disease 
results from unregulated stimulation of the thyrotropin (TSH) receptor by autoreactive 
TSH-receptor antibodies (TRAbs) which are detectable in virtually every patient with 
the disease3. Patients with uncorrected hyperthyroidism have an increased mortality 
risk and suffer significant cardiovascular morbidity including cardiac arrhythmias, 
strokes and heart failure4,5. Three treatment modalities for Graves’ disease, namely 
thionamide drugs, radioactive iodine, and thyroidectomy have been available for 
decades, all with established safety and efficacy records. However, the approach to 
therapy is highly variable and largely dictated by regional preferences2,6. Primary 
thionamide therapy is favoured by the European Thyroid Association7, while the 
American Thyroid Association endorses any of the modalities depending on individual 
patient characteristics8. In practice radioiodine is traditionally preferred in North 
America9 although antithyroid drugs are increasingly used and are now the most 
common treatment for Graves’ disease in the United States 10. In contrast primary 
radioiodine therapy is less popular in Europe and Asia and remains restricted to 
patients who relapse following 12-18 months of thionamides112.  
These variations in treatment are in part driven by lack of evidence regarding mortality 
risk with respect to Graves’ disease management. Randomised controlled trials on 
mortality outcomes in Graves’ disease are lacking and are unlikely to be undertaken 
given the logistic implications. Although observational studies have addressed 
mortality end-points in patients with hyperthyroidism4,12-18, only a few studies 
specifically distinguished Graves’ disease from other causes of hyperthyroidism17,19-
23. This distinction is relevant given that Graves’ disease patients are younger and 
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express a different cardiovascular phenotype from those with thyroid nodules2,5,20,22. 
In addition, unlike patients with toxic nodules who require definitive treatment for cure, 
Graves’ disease patients have a choice of all three treatments, underpinning the need 
for treatment-specific outcome data. 
Although previous cohort studies have reported excess mortality in radioiodine-treated 
patients15,17,18,23,24, these cohorts excluded patients treated with thionamides which 
currently represents the predominant therapy modality for Graves’ disease worldwide2. 
Only one study to date has compared mortality according to thionamide versus 
radioiodine treatment19. The study by Boelaert et al observed reduced mortality after 
radioiodine induced hypothyroidism compared to during thionamide therapy. However, 
the study comprised a heterogeneous hyperthyroidism clinic cohort (n=1036) that was 
underpowered to show treatment effects in the Graves’ disease subset (n=345)19. 
Thus, it remains unclear whether primary radioiodine therapy offers survival 
advantages over thionamides and hence whether current Graves’ disease treatment 
strategies are optimal. Our objective in the present study was to evaluate 
cardiovascular morbidity and mortality according to the modality and effectiveness of 
primary therapy in a large cohort of patients with Graves’ disease.  
METHODS 
Data Sources and study population  
The study was conducted through linked datasets within the Secure Anonymised 
Information Linkage (SAIL) Databank. SAIL is a nationwide repository of routinely 
collected health and social care data in Wales run by the Health Informatics Research 
Unit of Swansea University. The databank contains over two billion anonymised 
person-based records linked to hospital admission and primary care data25. All 
National Health Service (NHS) users in Wales are identified by a unique 10-digit 
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identifier and anonymity of data within the databank is ensured by multi-party 
encryption through a split-file data management system26. For this study, we created 
a dataset of patients with hyperthyroidism, diagnosed between January 1998 and 
December 2013 in clinics across three health boards serving an estimated 1·4 million 
residents in South Wales. We included all patients who could be linked to the Welsh 
Demographic Service, a population register of individuals registered with a general 
practitioner (GP) or receiving healthcare in Wales. Additional outcomes were obtained 
from primary care data held within SAIL, covering about 75% of the population, and 
the Patient Episode Database for Wales (PEDW), a dataset of all inpatient admissions 
in Wales.  
Patients with Graves’ disease were identified from electronic records of TRAb tests 
performed at the biochemistry department of the University Hospital of Wales, Cardiff, 
which served as the regional TRAb-assay laboratory during the period covered by the 
study. TRAbs are sensitive and specific markers of Graves’ disease27 and are routinely 
included in the diagnostic work-up of Graves’ disease in our catchment clinics. 
Patients were defined as Graves’ Hyperthyroidism if they had a positive TRAb test 
together with evidence of hyperthyroidism from either: (a) low-TSH in laboratory 
records, (b) record of hyperthyroidism in GP or hospital datasets (ICD-10 E05, read 
codes C02), or (c) record of thionamide prescription in GP data (carbimazole, read 
codes fa1 and propylthiouracil, fa2). The patient inclusion flow chart is presented in 
figure 1. For a background control population, we identified a sample of individuals in 
the Welsh Demographic Service, matched to cases on birth week and sex, at a ratio 
of 4 control subjects per patient (n=16,756). Individuals with hyperthyroidism on our 
loaded datasets were excluded from the controls.  
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Treatment and outcome data 
Iodine-131 treatment data was extracted from radioiodine treatment logs in nuclear 
medicine departments serving the study population. Each department holds statutory 
records of all radioisotope treatment including isotope type, dose, and date of 
administration. Information on thyroidectomy was obtained from PEDW using the 
Office of Population censuses and Surveys version 4 (OPCS-4) classification code for 
thyroidectomy, B081-B091. Outcome events were recorded from PEDW using the 
relevant ICD-10 codes for atrial fibrillation (I48), acute myocardial infarction (I21-I23), 
acute coronary syndrome (I20), heart failure (I50), ischaemic stroke (I63, I65-I68), 
haemorrhagic stroke (I60-I62), diabetes mellitus (E10-E14), thyroid cancer (C73), and 
breast cancer (C50). Mortality information was obtained from the Office for National 
Statistics (ONS). 
Laboratory assays 
TRAbs were performed with second generation radioimmunoassays while thyroid 
hormones (FT4 and TSH) were performed using several different immunoassays. The 
laboratory assays, reference ranges and performance measures are detailed in the 
supplementary appendix and supplementary table 1. 
Statistical analysis 
Baseline data is summarised as means (standard deviation, SD) for normally 
distributed values or median (interquartile range, IQR) for non-normal data. 
Differences between groups were analysed with chi-squared test, 2-tailed t-test or 
Mann-Whitney tests as appropriate. The primary study outcome was all-cause 
mortality while secondary outcome was major adverse cardiovascular events (MACE), 
a composite of acute myocardial infarction, ischaemic stroke, heart failure, or death. 
Patients were grouped according to primary treatment using a landmark approach to 
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avoid immortal time bias. The landmark was set at one-year post-diagnosis which was 
considered sufficient time for primary therapy without incurring excessive data losses 
from pre-landmark censoring.  
Treatment groups comprised: (1) ATD, patients who received only antithyroid drugs in 
the first year of diagnosis, (2) RAI-Grp-A, patients who received radioiodine and 
achieved hyperthyroidism control by one-year, and (3) RAI-Grp-B, patients who 
received radioiodine but had not achieved hyperthyroidism control by one-year. We 
excluded patients if they were censored before one-year (n=93) or had thyroidectomy 
in the first-year due to small numbers (78 patients, 2 deaths). Control of 
hyperthyroidism after radioiodine was defined as levothyroxine initiation, or TSH above 
the reference limit, or persistent euthyroidism (>6 months), each without antithyroid 
drug use. The diagnosis date was the date of the first positive TRAb or low-TSH, 
whichever was recorded earlier, and follow-up was from diagnosis until event or study 
end.  
We analysed outcomes according to primary treatment using Kaplan-Meier curves and 
Cox regression models. First, we compared event rates in patients and population 
controls using the logrank test and an adjusted Cox regression model to account for 
baseline comorbidity. The analysis was undertaken in the whole cohort and stratified 
by primary treatment group, with the corresponding matched population for each group 
as controls. In a second approach, we used a Cox regression model to compare event 
risk between treatment groups with the antithyroid drug group as reference category. 
Models were adjusted for 5-year age bands, gender, diagnosis-year, baseline TRAb 
concentration, and comorbidity scores, using a modification of the Charlson 
Comorbidity Index (supplementary table 2). Stratified analysis was undertaken by age 
(>50 vs. <50 years) and co-morbidity score (0 vs >1) with interaction terms for sub-
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groups. In sensitivity analysis, we sequentially excluded pregnant patients (n=63) and 
patients with borderline TRAb levels (n=266) at diagnosis. The validity of the 
proportional hazard assumption was examined by Schoenfeld residuals test and visual 
inspection of residuals plots against time.  
As an alternative means of handling time bias, treatment and thyroid status were 
incorporated as time-dependent covariates in a multivariable Cox proportional hazard 
regression model in which patients contributed person-time as follows: (1) ATD, from 
diagnosis to definitive treatment with radioiodine or thyroidectomy; (2) RAI without 
hyperthyroidism control, from radioiodine therapy until control of hyperthyroidism, (3) 
RAI with hyperthyroidism control, following radioiodine control of hyperthyroidism; (4) 
Thyroidectomy, following thyroidectomy.  
To directly evaluate the impact of thyroid status, we analysed outcomes according to 
thyroid function after one-year of treatment. We derived a one-year FT4 and TSH from 
time-weighted averages of all available tests at 9–12 months excluding patients 
censored before one-year. TSH was entered in a Cox regression model as low, 
normal, or high-TSH with the normal-TSH as reference category. Models were 
adjusted for age, gender, comorbidity, baseline TRAb, FT4 and TSH, and then 
stratified by primary treatment modality based on treatment received by the test date. 
For FT4, we used restricted cubic splines to model a possible non-linear relationship 
between one-year FT4 and outcomes. Four equally-spaced knots were set at 
percentiles 5, 35, 65 and 95 according to Harrell’s recommendation28. To account for 
differences in assay methods, FT4 was converted to multiples of the upper limit of the 
assay reference range (ULN). Restricted cubic splines were also used to model the 
longitudinal FT4 change in in the first 24-months of treatment with cubic knots set at 
0, 3, 6, 9, 12, and 18 months.  
12 
 
Serial thyroid function tests were missing in 29% of patients. The characteristics of 
patients with thyroid tests were comparable to those with missing tests except that 
patients with tests were younger (mean age 47 vs 49 years, P<0.001), and missing 
tests were more frequent in patients treated with antithyroid drugs compared to 
radioiodine or surgery (37% vs 3% vs 16%, P<0.001) (supplementary appendix, 
supplementary table 3). Thus, we addressed missing tests in the one-year TSH 
analysis using multiple variable imputation by chained equations29 under the missing 
at random assumption (supplementary appendix). We generated 50 imputed datasets 
with 500 iterations and fitted Cox proportional models within each dataset after which 
estimates were pooled according to Rubin’s rules. Sensitivity analysis using a 
complete case analysis gave similar results, so we report results from the imputed 
datasets while the complete case analysis is presented in the supplementary 
appendix. Statistical analysis was performed via remote desktop with the SAIL 
Databank using Stata version 16 for Windows (Stata Corp., College Station, TXS, 
USA).  
Regulatory Approvals 
The study was registered with the Research and Development Office of Cwm Taf 
Health Board and approval for data linkage with individual health boards was obtained 
(reference CT/688/140049/16). Approval for access to anonymised data in the SAIL 
databank was granted by the SAIL Information Governance Review panel (project 
reference, 0233). Ethical permission is granted for conducting data analysis in the 
SAIL Databank and separate ethics committee review was not required for this study.  
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Role of the funding source 
The funding source had no role in study design, data analysis, or writing of the report. 
The corresponding author had full access to all the data in the study and had final 
responsibility for the decision to submit for publication. 
RESULTS 
The final study cohort comprised 4,189 TRAb-positive patients with Graves’ disease 
and 16,756 controls, with follow-up ranging from 6 months to 16·8 years in the SAIL 
databank. Baseline characteristics are presented in table 1. 82% of patients were 
females with peak age 30–60 years. Overall, antithyroid drug treatment alone was 
used in 74% of patients while 20% and 6% received radioiodine or thyroidectomy 
respectively. Of the whole cohort, 4,019 patients with at least one-year follow-up were 
eligible for inclusion in the landmark analysis including 3,587 patients treated with 
antithyroid drugs (ATD) alone in the first-year, 250 radioiodine-treated patients with 
resolved hyperthyroidism by one-year (RAI-Grp-A), and 182 radioiodine-treated 
patients with unresolved hyperthyroidism by one-year (RAI-Grp-B). The 
characteristics of the landmark cohort is presented in Supplementary table 4. As in the 
full cohort, radioiodine treated patients were older than medically-treated patients 
(mean age 53 vs 47 years) and had more severe disease at diagnosis in terms of 
higher baseline levels of FT4 and TRAbs than ATD patients. Although both radioiodine 
groups were well-balanced in baseline characteristics and iodine-131 dose (median 
555 Mbq), RAI-Grp-A patients received earlier iodine-131 treatment than RAI-Grp-B 
(median time to treatment of 108 vs 188 days).  
Overall, 228 deaths (5·4%) were recorded in patients compared to 765 (4·6%) in 
controls. Crude and adjusted Cox regression models for mortality and other events 
are presented in table 2. Patients had increased mortality (HR 1·23, 95%CI 1·06, 1·42) 
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and MACE (HR 2·47, 95%CI 2·16, 2·81) compared to controls and also had increased 
risks for atrial fibrillation, congestive cardiac failure, and ischaemic stroke (table 2). 
Figure 2 shows survival curves in patients versus controls, presented for the whole 
cohort and stratified by primary treatment groups. The adjusted Cox regression model 
showed an increase in mortality and MACE in all treatment groups apart from RAI-
Grp-A patients (HR 0·65, 95%CI 0·38, 1·13). Logrank tests gave consistent results 
with the adjusted model except for mortality in RAI-Grp-B (figure 2d) and MACE in 
RAI-Grp-A (figure 2g) which failed to reach significance by logrank but were significant 
in the adjusted model. The results remained unchanged when all treatment groups 
and the control population were included in an adjusted Cox regression model with a 
shared frailty term for case-control clusters. 
Between-group comparisons are shown in figure 3. RAI-Grp-A patients had reduced 
risk of mortality (HR 0·50, 95% CI 0·29, 0·85) and MACE (HR 0·59, 95% CI 0·38, 0·92) 
compared to the ATD group. In contrast, RAI-Grp-B patients had an increase in MACE 
risk (HR 1·52, 95% CI 1·01, 2·28) with no survival advantage over ATD patients. 
Similar results were seen in sub-groups without comorbidity but not those with 
comorbidity (P for interaction 0.039). There was no interaction with age (>50 vs <50 
years) and results remained unchanged after excluding pregnant patients or patients 
with borderline TRAbs (supplementary tables 5 and 6).  
The results of the time-dependent multivariable analysis are presented in 
supplementary tables 7 and 8. The models incorporated serial thyroid hormones and 
treatment modality as time-dependent variables. Mortality and MACE risk increased 
with age, male gender, and co-morbidity but reduced with increasing year of diagnosis 
possibly reflecting temporal improvements in overall cardiovascular survival. 
Increased risk of mortality and MACE was observed with increasing levels of serial 
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FT4 but not serial TSH. With respect to treatment, reduced mortality and MACE risk 
was seen after radioiodine induced control of hyperthyroidism compared to during 
antithyroid drug therapy. In contrast reduced mortality was not seen after radioiodine 
therapy that had not controlled hyperthyroidism or after thyroidectomy although there 
was low power due to fewer thyroidectomies (supplementary table 7–8).  
To evaluate the influence of thyroid status on outcomes we analysed the relationship 
of TSH at one-year with mortality and MACE using a landmark Cox regression model 
(figure 4). Of the patients with a one-year TSH, 898 (39%) had low-TSH while 429 
(19%) had high-TSH. The fully adjusted model showed increased mortality and MACE 
risk with Low-TSH but not high-TSH (figure 4). This association was observed in the 
whole cohort as well as in the antithyroid drug group with no significant interaction with 
treatment (P value for interaction of 0.325 and 0.565 for mortality and MACE 
respectively, figure 4). Similar results were obtained from the imputation model (figure 
3) and the complete case analysis (supplementary figure 1).  
The relationship between FT4 and outcomes was modelled with restricted cubic 
splines which showed increasing hazard with FT4 concentrations above the reference 
range (figure 5). This relationship was seen in the whole cohort and in drug-treated 
patients but not radioiodine-treated patients (figure 5). Cubic splines were also used 
to model the longitudinal change in FT4 after diagnosis. All treatment groups showed 
a rapid drop in FT4 after diagnosis which was most pronounced and sustained in the 
successfully treated radioiodine group (supplementary figure 2).  
DISCUSSION 
We have used linked health records to evaluate all-cause mortality and cardiovascular 
event risk in patients with Graves’ disease and compared outcomes according to the 
modality and effectiveness of primary treatment. Compared to population controls, 
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Graves’ disease patients had a 23% increase in all-cause mortality and over twice the 
risk of a major cardiovascular event. Furthermore, early and successful treatment with 
radioiodine was associated with a 50% reduction in mortality compared to primary 
treatment with antithyroid drugs. Notably, survival advantages were not seen in 
radioiodine treated patients who failed to achieve control of hyperthyroidism. Patients 
with persistently low-TSH after one-year of treatment had a 55% increase in mortality 
even in patients treated with antithyroid drugs alone. Thus, for the first time, we show 
that mortality in patients with Graves’ disease is reduced by early and intensive 
correction of hyperthyroidism regardless of therapy modality. 
Our findings confirm the increased mortality risk previously reported in some19,20,22 but 
not all17,30 hyperthyroidism outcome studies. However, only a few studies to date have 
specifically addressed mortality risk in relation to hyperthyroidism treatment. Previous 
large-scale cohort-studies suggested an excess of cardiovascular mortality in 
radioiodine-treated patients compared to the background population15,17,18,31. A 1980s 
United States thyroid clinic study observed no difference in mortality between 
radioiodine and thyroidectomy-treated women32 whereas more recent registry studies 
from Finland 24 and Sweden23 have reported survival advantages of thyroidectomy 
over radioiodine treatment. The interpretation of these data is clearly constrained by 
study designs that excluded thionamide-treated patients15,17,18,23,24,31,32, failed to 
account for thyroid status23,31,32, and did not control for bias from uneven time-intervals 
preceding definitive therapy15,17,18,31,32. In their Birmingham clinic study, Boelaert et al 
applied a time-dependent regression model that incorporated thyroid status to show 
survival benefits relative to thionamides following radioiodine-induced 
hypothyroidism19. However, their study was underpowered to show benefits in the 
Graves’ disease subset19.  
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In the present study, we have employed a study design that distinguished treatment 
effects from the effects of hyperthyroidism to show that the predictor of cardiovascular 
morbidity and mortality is the effectiveness of primary treatment rather than therapy 
modality per se. Our one-year TSH analysis shows that the excess mortality in Graves’ 
disease is driven by exposure to uncontrolled hyperthyroidism and that elimination of 
the hyperthyroid state whether with antithyroid drugs or radioiodine yields survival 
benefits. This is biologically plausible given the established association of 
hyperthyroidism with cardiovascular disease4 and is consistent with a recent Danish 
register-based study that reported excess mortality in association with cumulative 
periods of low-TSH in patients with treated and untreated hyperthyroidism14. 
Subsequent analyses of the Danish register also showed increased mortality with 
cumulative hypothyroidism exposure33 highlighting the need for strict surveillance of 
therapy to avoid periods of uncontrolled hypothyroidism or hyperthyroidism. As our 
data shows, persistent thyroid dysfunction is common during Graves’ disease therapy, 
with low or high TSH recorded in 58% of patients at one-year.  
The choice of primary therapy in Graves’ disease is currently driven by regional 
preferences7,8. Our findings indicate that a greater value should now be placed on the 
rapid elimination of hyperthyroidism with maintenance of a normal-TSH as standard 
of care. Thus, patients with unfavourable characteristics for thionamide-induced 
relapse such as severe disease, or high TRAb levels should be offered primary 
radioiodine therapy. The use of radioiodine should be governed by treatment protocols 
designed to optimise treatment success through efficient patient preparation and 
administration of ablative doses of iodine-131. Primary definitive treatment will not be 
a priority for patients with mild disease and in such cases thionamides should be used 
at doses and duration that promote rapid and sustained control of hyperthyroidism.  
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The strength of our study is the unique dataset of 4,189 TRAb-positive Graves’ 
disease patients with long-term follow-up and robust and innovative data linkage. Ours 
is the first large-scale hyperthyroidism cohort study to exploit TRAbs as a specific 
Graves’ disease marker, thereby excluding patients with toxic nodules, thyroiditis, or 
non-thyroidal illness. By employing a landmark regression approach, we eliminated 
treatment time bias and additionally provided a clinically relevant time-point from which 
to evaluate primary therapy. Our study limitation is that the retrospective design could 
have introduced bias from undocumented confounders such as smoking, orbitopathy, 
physician treatment preference, patient compliance with thionamides, and unrecorded 
exposure to thyroid hormone excess. However, our adjustments for comorbidity and 
biochemical characteristics would to some extent have adjusted for these 
confounders. In keeping with conventional practice, patients with more severe 
baseline disease received radioiodine, but it is unlikely that this influenced our results 
given that both radioiodine-treated groups had similar baseline features yet strikingly 
divergent outcomes. Lastly, thyroid tests were missing in a proportion of patients. 
However, we minimised potential bias from this using principled imputation methods 
and robust sensitivity checks. Ultimately, potential confounders will only be fully 
addressed in well-designed, randomised controlled trials which are yet to be 
undertaken.  
In conclusion, early and intensive control of hyperthyroidism in Graves’ disease is 
associated with improvements in long-term cardiovascular morbidity and mortality 
regardless of therapy modality. Greater emphasis should now be placed on ensuring 
prompt elimination of hyperthyroidism and maintenance of a normal thyroid status in 
the management of Graves’ disease.  
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   Treatment groups  
 Population controls All Patients  Antithyroid drugs Iodine-131 Thyroidectomy  
 n=16756 n=4189  n=3094  n=829  n=266  P for trend c 
Age, yrs       
 Mean + SD 48 + 16 48 + 16 48 + 16 50 + 16 39 + 13 <0·001 
 <20 204 (1·2) 51 (1·2) 37 (1·2) 6 (0·7) 8 (3·0) <0·001 
 20-29 2176 (13·0) 544 (13·0) 402 (13) 83 (10·0) 59 (22·2)  
 30-39 3420 (20·4) 855 (20·4) 626 (20·2) 138 (16·6) 91 (34·2)  
 40-49 3688 (22·0) 922 (22·0) 667 (21·6) 195 (23·5) 60 (22·6)  
 50-59 3240 (19·3) 810 (19·3) 601 (19·4) 184 (22·2) 25 (9·4)  
 60-69 2340 (14·0) 585 (14·0) 443 (14·3) 124 (15·0) 18 (6·8)  
 >70 1688 (10·1) 422 (10·1) 318 (10·3) 99 (11·9) 5 (1·9)  
Sex       
 Female 13656 (81·5) 3414 (81·5) 2527(81·7) 656 (79·1) 231 (86·8) 0·017 
 Male 3100 (18·5) 775 (18·5) 567 (18·3) 173 (20·9) 35 (13·2)  
Comorbidity        
 Absent 15453 (92·2) 3599 (85·9) 2647 (85·6) 715 (86·2) 237 (89·1) 0·263* 
 Present 1303 (7·8) 590 (14·1) 447 (14·4) 114 (13·8) 29 (10·9)  
TRAb IU/L — 6·9 (3·1, 16·8) 6·0 (2·8, 13·6) 11·3 (4·1, 26·4) 15·9 (5·8, 36·3)  <0·001 
Thyroid status       
 FT4, pmol/La — 31·8 + 22·0 29·5 + 19·7 36·2 + 25·4 36·5 + 25·6 <0·001 
 FT4 >40 pmol/La — 719 (24) 390 (20) 255 (32) 74 (33) <0·001 
Person years follow up 103374 25266 16481 6878 1907  
TABLE 1: Baseline characteristics of the whole cohort  
Data represents numbers (%), mean + SD, or median (interquartile range).  a, data available for 2962 patients, TRAb, TSH receptor antibody; c, P values are for trend 
across treatment categories. Patients and controls were matched for age· *Comorbidity was increased in patients compared to controls (P<0·001) 
26 
 
 
 
 
 
Outcome 
Number of cases (%)  
Graves’ disease 
N=4189 
Controls a 
N=16756 Crude HR (95% CI) P value Adjusted HR (95 CI) b P value 
All-cause Mortality 228 (5·4) 765 (4·6) 1·22 (1·05, 1·42) 0·008 1·23 (1·06, 1·42) 0·033 
MACEc 329 (7·9) 651 (3·9) 2·18 (1·91, 2·48) <0·001 2·47 (2·16, 2·81) <0·001 
Atrial Fibrillation 240 (5·7) 379 (2·3) 2·62 (2·23, 3·08) <0·001 2·67 (2·25, 3·15) <0·001 
Acute Myocardial Infarction 38 (0·9) 122 (0·7) 1·26 (0·87, 1·81) 0·220 1·22 (0·84, 1·76) 0·287 
Acute coronary syndrome 32 (0·8) 74 (0·4) 1·75 (1·15, 2·65) 0·008 1·65 (1·09, 2·51) 0·018 
Congestive Cardiac Failure 109 (2·6) 240 (1·4) 1·85 (1·47, 2·31) <0·001 1·78 (1·42, 2·23) <0·001 
Ischaemic Stroke 41 (1·0) 98 (0·6) 1·70 (1·17, 2·43) 0·005 1·60 (1·11, 2·30) 0·012 
Haemorrhagic Stroke 14 (0·3) 37 (0·2) 1·53 (0·83, 2·83) 0·175 1·50 (0·81, 2·78) 0·196 
Type 1 Diabetes 29 (0·7) 42 (0·3) 2·71 (1·68, 4·37) <0·001 2·53 (1·56, 4·08) <0·001 
Type 2 Diabetes 170 (4·1) 474 (2·8) 1·46 (1·23, 1·74) <0·001 1·39 (1·16, 1·66) <0·001 
All Diabetes 199 (4·8) 516 (3·1) 1·57 (1·33, 1·85) <0·001 1·46 (1·24, 1·71) <0·001 
Thyroid Cancer 8 (0·2) 5 (0·0) 6·52 (2·13, 19·93) <0·001 6·67 (2·18, 20·41) 0·001 
Breast Cancer 38 (0·9) 143 (0·9) 1·08 (0·76, 1·55) 0·442 1·06 (0·74, 1·52) 0·798 
TABLE 2: Hazard ratios for mortality, MACE, and other events  
a Controls are matched for age and sex b Hazard ratios are derived from Cox proportional models adjusted for age, sex and comorbidity, c MACE, major adverse 
cardiovascular event comprising acute myocardial infarction, congestive cardiac failure, ischaemic cerebrovascular accident, or death  
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FIGURE 1: Study flow chart 
TRAb, TSH receptor antibody; ATD, Antithyroid Drugs; RAI, radioactive iodine; RAI-Group-A, radioiodine with hyperthyroidism 
control by one-year, and RAI-Group-B, radioiodine without hyperthyroidism control by one-year; *Numbers add up to 171 for 170 
patients because one patient had thyroidectomy and died in the first year.  
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FIGURE 2: Kaplan Meier curves for mortality or MACE   
Kaplan Meier curves for cumulative mortality (panels A-D) or MACE (panels E-H) in the whole cohort and by primary treatment. ATD, patients who 
received antithyroid drugs alone in the first one-year, RAI-Group-A, radioiodine with hyperthyroidism control by one-year, and RAI-Group-B, radioiodine 
without hyperthyroidism control by one-year. HR, Hazard ratios derived from Cox regression models adjusted for age, sex, and comorbidity. 
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FIGURE 3: Hazard ratios for mortality or MACE by primary treatment  
HR (95% CI) are obtained from multivariable Cox proportional hazard regression models. ATD, patients who received antithyroid 
drugs alone in the first one-year, RAI-Group-A, radioiodine with hyperthyroidism control by one-year, and RAI-Group-B, radioiodine 
without hyperthyroidism control by one-year. P-value, for association; P-int, P values for interactions with comorbidity and age.  No 
comorbidity=comorbidity score 0; comorbidity=comorbidity score >1 
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FIGURE 4: Hazard ratios for mortality or MACE by one-year TSH 
HR (95% CI) are obtained from multivariable Cox proportional hazard regression models. Analysis was conducted in all patients and in 
treatment subgroups according to treatment in the first-year with antithyroid drugs (ATD) or radioactive iodine (RAI). P-int, P values for 
interaction with treatment group.  
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FIGURE 5: One-year FT4 and mortality and MACE  
Relationship between FT4 at one-year and All-cause mortality (A-C) and MACE (D-F). Curves represent log 
hazard ratios, 95% CI derived from restricted cubic spline regressions with 4-equally spaced knots at 
percentiles 5, 35, 65 and 95 respectively. FT4 is in multiples of the upper reference limit (x ULN) with the 
reference value set at FT4 x 0.75 ULN. Results were obtained from Cox regression models adjusted for age, 
gender, TRAb concentration, comorbidity, and year of diagnosis. P values are for overall association (P-
overall) and non-linearity (P-non-linearity) 
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Primary therapy of Graves’ disease and cardiovascular morbidity and mortality: 
a linked-record cohort study  
Supplementary Appendix 
Supplementary Methods 
Modified Charlson Comorbidity Scores 
Comorbidity scores were derived using a modification of the Charlson Comorbidity 
Index (CCI) 1. Individual scores were calculated as the sum of weighted scores for 
each of 17 disease conditions identified from hospital admission data using ICD-10 
codes for secondary diagnosis fields (DIAG2-DIAG14) 2,3 (supplementary table 1).  
Laboratory assays 
Between January 1998 and April 2004 TSH receptor antibodies (TRAbs) were 
measured with a 2nd generation radioimmunoassay (RIA) based on inhibition of 
labelled TSH binding to TSH receptor coated tubes, RSR Limited, Cardiff 4,5. The 
assay reference ranges were: <1.0, negative, 1.0-1.5 borderline >1.5, positive with 
analytical range of 1—40 U/L, and lower detection limit of 0.33 U/L. The sensitivity of 
the assay was 92.0% with specificity of 100%. Between April 2004 and December 
2013, TRAbs were measured with a 2nd generation RIA which was also based on 
inhibition of radio-labelled TSH binding to TSH receptor coated tubes, B.R.A.H.M.S. 
TRAK human, Thermo Scientific 6. The assay reference ranges were: <1.0, negative, 
1.0-1.5 borderline, and >1.5, positive, with analytical range of 1—40 U/L, functional 
sensitivity of 1.0 +/- 0.2 U/L and analytical sensitivity of 0.3 U/L. The sensitivity of the 
assay was 98.8% with specificity of 99.6%. The assay principles, performance, and 
reference ranges for thyroid function tests (FT4 and TSH) are presented in 
supplementary table 2. To account for differences in assay methods, FT4 was 
transformed to multiples of the upper limit of the assay reference range (ULN) and 
TSH was categorised as low, normal or high-TSH according to the assay reference 
range. 
Restricted Cubic Spline Regression 
We modelled a potential non-linear relationship between the FT4 concentration at one 
year and mortality or MACE using restricted cubic spline regressions. Cubic splines 
allow flexible smooth transformations of the relationship between a quantitative 
covariate and an outcome 7. We used the mkspline co-mmand in Stata to set 4 equally-
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spaced knots at percentiles 5, 35, 65 and 95 according to the recommendation by 
Harrell 8. Varying the positions of the knots did not significantly influence our estimates. 
The reference values were set at the FT4 assay upper limit (x 1.0). Predicted hazard 
ratios (HR) were derived from Cox regression models adjusted for age, gender, year 
of diagnosis, baseline TRAb concentration, and comorbidity. We used the xblc post-
estimation package in Stata to plot the regression between FT4 and log HR for 
mortality/MACE. Models were fitted for the whole cohort and then stratified by 
treatment. P values for non-linearity were obtained using likelihood ratio tests. We also 
used cubic splines to model longitudinal change in FT4 concentration in the first year 
of treatment with cubic knots set at 0, 3, 6, 9, and 12 months.  
Missing data imputation 
Serial thyroid function tests were available for patients with Graves’ disease but not 
for the control population. Thyroid function tests were missing in 29% of patients. One-
year TSH was available in 80% of patients with serial thyroid function tests equivalent 
to 57% of the eligible landmark cohort. All other variables had complete data. Missing 
thyroid tests were due to lack of electronic access and linkage of laboratory data to 
the SAIL databank from some laboratories at various study time segments. Where 
laboratory linkage occurred, thyroid tests were available in >90% of patients in clinics 
served by the laboratory, reducing the likelihood of confounding by data not missing 
at random.  
The characteristics of patients with missing and non-missing thyroid tests is shown in 
supplementary table 3. Patients with missing tests were older (49 vs 47 years) and 
missing tests were more frequent in patients treated with antithyroid drugs compared 
to radioiodine or surgery (37% vs 3% vs 16%, P<0.001). Patients with missing tests 
also had lower TRAb levels (median 5.8 vs 7.8 IU/L) but in logistic regression, the only 
factors associated with thyroid test missingness were older age (OR 1.01, 95%CI 1.00, 
1.02 per year increase in age) and treatment with antithyroid drugs (OR 2.28, 95%CI 
1.61, 3.23, antithyroid drugs vs radioiodine/Surgery). Missingness was not associated 
with sex, comorbidity, TRAB concentration, mortality or MACE. Thus, we assumed the 
data were not ‘Missing Completely at Random, (MCAR)’ but were ‘Missing at Random, 
(MAR)’.  
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In the one-year TSH analysis we addressed missing tests using multiple variable 
imputation by chained equations 9. The imputation model comprised all predictor and 
outcome variables in the analysis. We generated 50 imputed datasets and fitted Cox 
proportional models within each dataset after which estimates were pooled according 
to Rubin’s rules 10. In sensitivity analysis we repeated the analysis using a complete 
case analysis which showed identical estimates to the imputation model 
(Supplementary figure 1). To exclude the possibility that missingness at one-year was 
associated with stable or worse disease control, we modelled two sensitivity scenarios 
in which a normal-TSH and a low-TSH at one-year were assumed for patients with 
serial TSH but missing one-year TSH. These scenarios gave similar results to the 
imputation model (data not shown).  
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SUPPLEMENTARY FIGURE 1: Hazard ratios for mortality or MACE by one-year TSH, complete case analysis 
HR (95% CI) are obtained from multivariable Cox proportional hazard regression models. Analysis was conducted in all patients and in 
treatment subgroups according to treatment in the first-year with antithyroid drugs (ATD) or radioactive iodine (RAI). P-int, P values for 
interaction with treatment group. Results are obtained from a complete case analysis 
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SUPPLEMENTARY FIGURE 2: FT4 profile post-diagnosis  
Longitudinal profile of FT4 concentrations after diagnosis according to treatment groups. FT4 is in multiples of the 
upper limit of the reference range (X ULN); ATD, antithyroid drugs, RAI-Grp-A, radioiodine with control of 
hyperthyroidism by 12 months, RAI-Grp-B, radioiodine without control of hyperthyroidism by 12 months 
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  FT4, pmol/L TSH, mU/L 
Laboratory Assay method, platform Reference Interval CV (%) Reference Interval CV (%) 
Cardiff and Vale      
 Jan 1998 - May 2011 CCIA, ADVIA Centaur, Bayer1 9·8–23·1 2·31 at 13·9 pmol/L 0·35 - 5·50 2·44 at 5·65 mU/L 
 May 2011 - Jan 2013 CMIA, Abbott ARCHITECT2  9·0 –19·1* <10 at all levels 0·30 - 4·40 <10 at all levels 
Cwm Taf (1)      
 Jan 1998 - March 2007 CCIA, IMMULITE 2000, DPC3  10·3–24·5 <10 at all levels 0·4 - 4·0 <5·0 at all levels 
 March 2007 - Dec 2013 ECLIA, Roche E-1704 10·3–24·5 8·2 at 8·2 pmol/L 0·4 - 4·0 2·4 at 6·67 mU/L 
Cwm Taf (2)      
 Jan 1995 – April 2011 CCIA, ADVIA Centaur, Bayer1 10·0-25·0 <10 at all levels 0·35-5·50** <10 at all levels 
 April 2011-Sept 2012 CCIA, ADVIA Centaur, Bayer1 10·0-25·0 <10 at all levels 0·35-5·50 <10 at all levels 
 Sept 2012-Dec 2013 ECLIA, Roche E-1704 10·3–24·5 8·2 at 8·2 pmol/L 0·4 - 4·0 2·4 at 6·67 mU/L 
Aneurin Bevan (1)   
 
   
                                            1998-2006 CCIA, IMMULITE 2000, DPC3  11·5–22·7 <10 at all levels 0·4 - 4·0 <5 at all levels 
 2006-2013 CMIA, Abbott ARCHITECT2  9·0–19·1 4·8% at 23·3 pmol/L 0·30 - 4·40 4·1% at 26·8 mU/L 
Aneurin Bevan (2)       
  1998—2000 MEIA, Abbott Axsym2  9·0–19·1 4·6 at 15·4 pmol/L 0·30 - 4·40 4·9 at 2·8 mU/L  
2000—2006 CCIA, ADVIA Centaur, Bayer1 9·8–23·1 <10 at all levels 0·35 - 5·50 <10 at all levels  
2007—2013 CMIA, Abbott ARCHITECT2 9·0–19·1 <10 at all levels 0·30 - 4·40 <10 at all levels 
Supplementary Table 1: Thyroid hormone assays  
CV, coefficient of variation; CCIA, competitive chemiluminescent immunoassay, CMIA, chemiluminescent microparticle immunoassay; ECLIA, 
electrochemiluminescence immunoassay; MEIA, Microparticle Enzyme Immunoassay; 1. Bayer Diagnostics, Newbury, UK; 2.  Abbott Diagnostics, Maidenhead, 
Berks, UK; 3. Diagnostics Product Corporation, Llanberis, Wales; 4. Roche Diagnostics GmbH, Mannheim, Germany, *from January to December 2013 the 
reference range for this assay was changed to 9.2—21.0 pmol/L, **from September 2009 to April 2011, reference range for this assay was 0.3-6.0 mU/L  
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  Condition ICD-10 diagnosis codes Score 
Acute myocardial infarction I21, I22, I252 1 
Congestive heart failure I50 1 
Peripheral vascular disease I71, I790, I739, R02, Z958, Z959 1 
Cerebral vascular disease I60, I61, I62, I63, I65, I66, G450, G451, G452, G458, G459, G46, I64, G454, I670, 
I671, I672, I674, I675, I676, I677, I678, I679, I681, I682, I688, I69 
1 
Dementia F00, F01, F02, F051 1 
Pulmonary disease J40, J41, J42, J44, J43, J45, J46, J47, J67, J44, J60, J61, J62, J63, J66, J64, J65 1 
Connective tissue disease M32, M34, M332, M053, M058, M059, M060, M063, M069, M050, M052, M051, M353 1 
Peptic ulcer disease K25, K26, K27, K28 1 
Liver disease K702, K703, K73, K717, K740, K742, K746, K743, K744, K745 1 
Diabetes E109, E119, E139, E149, E101, E111, E131, E141, E105, E115, E135, E145 1 
Diabetes with complications E102, E112, E132, E142, E103, E113, E133, E143, E104, E114, E134, E144 2 
Hemiplegia or paraplegia G81, G041, G820, G821, G822 2 
Renal disease N03, N052, N053, N054, N055, N056, N072, N073, N074, N01, N18, N19, N25 2 
Cancer C0, C1, C2, C3, C40, C41, C43, C45, C46, C47, C48, C49, C5, C6, C70, C71, C72, 
C73, C74, C75, C76, C81, C82, C83, C84, C85, C883, C887, C889, C900, C901, C91, 
C92, C93, C940, C941, C942, C943, C945, C947, C95, C96 
2 
Metastatic cancer C77, C78, C79, C80 3 
Severe liver disease K729, K766, K767, K721 3 
HIV B20, B21, B22, B23, B24 6 
Supplementary Table 2: Modified Charlson Comorbidity Scores  
Reference 2,3 
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 Patients with available thyroid tests Patients with missing thyroid tests 
 All patients  Medical therapy Iodine-131 Thyroidectomy P for trend, 
treatment 
groups a 
All patients P value, 
missing vs non-
missing b 
 
n=2969  n=1950  n=796   n=223  n=1220 
Age, yrs        
 Mean + SD 47 + 16 46 + 16 50 + 16 39 + 13 <0·001 49 + 16 <0.001 
 <20 42 (1·4) 29 (1·5) 6 (0·8) 7 (3·1) <0·001 9 (0.7)  
 20-29 409 (13·8) 278 (14·3) 81 (10·2) 50 (22·4)  135 (11.1)  
 30-39 630 (21·2) 424 (21·7) 133 (16·7) 73 (32·7)  225 (18.4)  
 40-49 669 (22·5) 426 (21·9) 191 (24·0) 52 (23·3)  253 (20.7)  
 50-59 550 (18·5) 360 (18·5) 170 (21·4) 20 (9·0)  260 (21.3)  
 60-69 390 (13·1) 252 (12·9) 120 (15·1) 18 (8·1)  195 (16.0)  
 >70 279 (9·4) 181 (9·3) 95 (11·9) 3 (1·4)  143 (11.7)  
Sex        
 Female 2422 (81·6) 1596 (81·9) 633 (79·5) 193 (86·5) 0·050 992 (81.3) 0.841 
 Male 547 (18·4) 354 (18·2) 163 (20·5) 30 (13·5)  228 (18.7)  
Comorbidity         
 Absent 2564 (86·4) 1678 (86·1) 688 (86·4) 198 (88·8) 0·532 1035 (84.9) 0.198 
 Present 405 (13·6) 272 (13·9) 108 (13·6) 25 (11·2)  185 (15.2)  
TRAb IU/L 7·8 (3·2, 18·4) 6·4 (2·9, 14·0) 11·4 (4·2, 27·0) 16·4 (5·6, 37·5)  <0·001 5.8 (2.75, 12.9) <0.001 
Thyroid status        
 FT4, pmol/L 31·8 + 22·0 29·5 + 19·7 36·2 + 25·4 36·5 + 25·6 <0·001 —  
 FT4 >40 
pmol/L 
719 (24) 390 (20) 255 (32) 74 (33) <0·001 —  
Missing tests 1220 (29) 1144 (37) 33 (4) 43 (16) <0.001 —  
Supplementary Table 3: Baseline characteristics in patients with missing and non-missing thyroid function tests  
Data represents numbers (%), mean + SD, or median (interquartile range).  TRAb, TSH receptor antibody; a, P values are for trend across treatment 
categories in patients with thyroid tests. b, P values are for difference between missing and non-missing tests.  
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 ATD RAI-Group-A  RAI-Group-B P value  
Number (%) 3587 (89%) 250 (6%) 182 (5%)  
Age     
 Mean + SD 46·9 + 15·8 52·6 + 15·0 52·9 + 15·8 <0·001a, b 
 Range 18-92 19-88 20-92  
Gender     
 Male 642 (17·9%) 55 (22·0%) 41 (22·5%) 0·089 
 Female 2945 (82·1%) 195 (78·0%) 141 (77·5%)  
Comorbidity     
 Present 485 (13·5%) 35 (14·0%) 30 (16·5%) 0·728 
 Absent 3102 (86·5%) 215 (86·0%) 152 (83·5%)  
TRAbs, U/L 6·7 (3, 15·8)  11·2 (4·1, 26·6)  11·4 (4·4, 26·1)  <0·001a, b 
Radioiodine therapy     
 Dose, Mbq - 555 (546, 563) 555 (544, 566) 0·984d 
 Days from diagnosis to treatment - 108 (53, 178) 188 (88, 302) <0·001 d 
FT4, pmol/L      
 Baseline  31·2 + 21·8 35·2 + 25·2 34·8 + 21·7 <0·003a, b 
 12 months 17·4 + 9·3 15·9 + 7·3 21·5 + 10·6 <0·001a, b, c 
 Baseline – 12 months  16·1 + 23·0 21·1 + 26·9 13·9 + 21·3 <0·001b, c 
TSH at 12 months, mU/L     
 Low 770 (39·6%) 44 (18·9%) 84 (64·6%) <0·001 a, c 
 Normal 905 (46·5%) 41 (17·7%) 36 (27·7%)  
 High 272 (13·9%) 147 (63·4%) 10 (7·7%)  
Supplementary Table 4: Characteristics of patients in the one-year landmark cohort  
a ATD vs RAI-Group-A, b ATD vs RAI-Group-B, c RAI-Group-A vs RAI-Group-B; ANOVA with pairwise comparisons with Tukey’s test; d 
RAI-Group-A vs RAI-Group-B, Kruskal Wallis; data is in numbers (%), mean + standard deviation, or median (interquartile range). Excluded 
patients who had surgery in the first 12 months (n=78) or <12 months survival (n=89). 
42 
 
 
   
 All-Cause Mortality MACE 
 Events/Total, N HR (95% CI) P value Events/Total, N HR (95% CI) P value 
Whole cohort       
 ATD 145/3527 1·00 (Ref)  176/3384 1·00 (Ref)  
 RAI-Group-A 13/236 0·47 (0·27, 0·83) 0·009 17/224 0·49 (0·30, 0·81) 0·005 
 RAI-Group-B 21/174 1·52 (0·96, 2·42) 0·083 21/159 1·49 (0·94, 2·35) 0·089 
No comorbidities       
 ATD 82/3047 1·00 (Ref)  118/2982 1·00 (Ref)  
 RAI-Group-A 4/201 0·20 (0·07, 0·56) 0·002 7/195 0·25 (0·12, 0·54) 0·001 
 RAI-Group-B 13/146 1·45 (0·80, 2·63) 0·195 16/137 1·68 (0·99, 2·84)                0·052 
Age>50 yrs       
 ATD 129/1502 1·00 (Ref)  152/1387 1·00 (Ref)  
 RAI-Group-A 11/137 0·43 (0·23, 0·79) 0·007 15/127 0·46 (0·27, 0·79)  0·005 
 RAI-Group-B 19/96 1·52 (0·93, 2·48) 0·102 17/84 1·36 (0·82, 2·25) 0·236 
Age<50 yrs                                                                          
 ATD 16/2025 1·00 (Ref)  24/1997 1·00 (Ref)  
 RAI-Group-A 2/99 1·04 (0·23, 4·79) 0·963 2/97 0·74 (1·70, 3·18) 0·680 
 RAI-Group-B 2/78 1·36 (0·31, 6·09) 0·691 4/75 2·32 (0·79, 6·78) 0·125 
Supplementary Table 5: Mortality and MACE by primary treatment: excluding pregnant patients  
HR (95% CI) are obtained from multivariable Cox proportional hazard regression models.  Analysis was conducted in all patients and in subgroups 
according to treatment in the first-year. ATD, Antithyroid drugs, RAI-Group-A, radioiodine treatment with control of hyperthyroidism, RAI-Group-B, 
radioiodine treatment without control of hyperthyroidism   
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 All-Cause Mortality MACE 
 Events/Total, N HR (95% CI) P value Events/Total, N HR (95% CI) P value 
Whole cohort       
 ATD 142/3353 1·00 (Ref)  166/3215 1·00 (Ref)  
 RAI-Group-A 13/229 0·46 (0·26, 0·82) 0·009 17/218 0·50 (0·30, 0·83) 0·007 
 RAI-Group-B 21/166 1·53 (0·96, 2·44) 0·071 19/151 1·38 (0·86, 2·33) 0·184 
No comorbidities       
 ATD 82/2903 1·00 (Ref)  114/2841 1·00 (Ref)  
 RAI-Group-A 4/197 0·20 (0·07, 0·54)  0·002 7/192 0·25 (0·12, 0·54) 0·001 
 RAI-Group-B 13/139 1·44 (0·79, 2·60) 0·119 15/130 1·62 (0·94, 2·77)                                  0·082
Age>50 yrs       
 ATD 126/1408 1·00 (Ref)  142/1297 1·00 (Ref)  
 RAI-Group-A 11/131 0·42 (0·22, 0·78) 0·006 15/121 0·48 (0·28, 0·82) 0·007 
 RAI-Group-B 19/89 1·53 (0·94, 2·50) 0·089 15/77 1·23 (0·72, 2·11) 0·443 
Age<50 yrs                                                                              
 ATD 16/1945 1·00 (Ref)  24/1918 1·00 (Ref)  
 RAI-Group-A 2/98 1·02 (0·22, 4·69) 0·984 2/97 0·72 (1·67, 3·11) 0·660 
 RAI-Group-B 2/77 1·38 (0·31, 6·16) 0·673 4/74 2·31 (0·79, 6·74) 0·126 
Supplementary Table 6: Mortality and MACE by primary treatment: excluding patients with borderline TRAbs  
Patients with borderline TRAbs (1.0-1.5 IU/L) were excluded. HR (95% CI) are obtained from multivariable Cox proportional hazard regression models.  
Analysis was conducted in all patients and in subgroups according to treatment in the first-year. ATD, Antithyroid drugs, RAI-Group-A, radioiodine 
treatment with control of hyperthyroidism, RAI-Group-B, radioiodine treatment without control of hyperthyroidism   
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 Model 1 Model 2 
 HR (95% CI) P value HR (95% CI) P value 
Age, years a 1·09 (1·08, 1·10) <0·001 1·09 (1·08, 1·10) <0·001 
Sex     
 Male 1·00 Ref 1·00 Ref 
 Female  0·57 (0·43, 0·76) <0·001 0·65 (0·47, 0·90) 0·010 
Co-morbidity     
 Absent 1·00 Ref 1·00 Ref 
 Present 3·07 (2·29, 4·13) <0·001 3·30 (2·36, 4·63) <0·001 
Year of diagnosis b 0·68 (0·58, 0·79) <0·001 0·63 (0·54, 0·79) <0·001 
Baseline TRAb c  1·15 (0·99, 1·32) 0·069 1·14 (0·96, 1·35) 0·144 
Thyroid hormones     
 Baseline FT4 d  — — 0·99 (0·99, 1·00) 0·474 
 Baseline TSH  — —   
  TSH 0.1—0·4 mU/L   1·00 Ref 
  TSH <0·1 mU/L   0·99 (0·95, 1·02) 0·384 
 Serial FT4 d — — 1·40 (1·11, 1·77) 0·005 
 Serial TSH     
  Normal/High — — 1·00 Ref 
  Low — — 1·00 (0·66, 1·54) 0.980 
Treatment     
 ATD 1·00 Ref  1·00 Ref 
 RAI without hyperthyroidism control 0·91 (0·67, 1·25) 0·571 0·97 (0·70, 1·36) 0·863 
 RAI with hyperthyroidism control 0·26 (0·08, 0·82) 0·022 0·27 (0·09, 0·87) 0·028 
 Thyroidectomy 0·60 (0·15, 2·44) 0·472 0·33 (0·05, 2·39) 0·272 
Supplementary Table 7: Multivariable analysis for all-Cause mortality  
HR (95% CI) are obtained from multivariable Cox proportional hazard regression models. Model 1, all patients, n=4189; Model 2, patients with 
thyroid function tests, n=2969; Serial thyroid hormones and treatment were set as time-dependent covariates. Patients contributed person-years 
of treatment from diagnosis to radioiodine treatment or thyroidectomy (ATD), following radioiodine to control of hyperthyroidism (RAI without 
hyperthyroidism control), following radioiodine and control of hyperthyroidism (RAI with hyperthyroidism control), and following thyroidectomy 
(thyroidectomy).   a, HR per 5-year increase in age; b, HR per 5-year increase in diagnosis year, c, HR per 10 IU/L increase in TRAb 
concentration, d, HR per 10 pmol/L increase in FT4 concentration 
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 Model 1 Model 2 
 HR (95% CI) P value HR (95% CI) P value 
Age, years  1·08 (1·07, 1·09) a <0·001 1·08 (1·07, 1·09) a <0·001 
Sex     
 Male 1·00 Ref 1·00 Ref 
 Female  0·56 (0·44, 0·71) <0·001 0·61 (1·07, 1·09) <0·001 
Co-morbidity     
 Absent 1·00 Ref 1·00 Ref 
 Present 2·91 (2·28, 3·72)  <0·001 2·95 (2·22, 3·91) <0·001 
Year of diagnosis  0·75 (0·67, 0·85) b <0·001 0·74 (0·64, 0·86) b <0·001 
Baseline TRAb  1·04 (0·93, 1·17) c 0·493 1·06 (0·92, 1·22) c 0·404 
Thyroid hormones     
 Baseline FT4  — — 0·99 (0·99, 1·00) d 0·618 
 Baseline TSH  — —   
  TSH 0.1—0·4 mU/L   1·00 Ref 
  TSH <0·1 mU/L   0·99 (0·96, 1·01) 0·317 
 Serial FT4 — — 1·52 (1·09, 1·94) d 0·007 
 Serial TSH     
  Normal/High — — 1·00 Ref 
  Low — — 1·00 (0·89, 1·78) 0.990 
Treatment     
 ATD 1·00 Ref 1·00 Ref 
 RAI without hyperthyroidism control 1·02 (0·78, 1·34) 0·857 1·08 (·081, 1·43) 0·601 
 RAI with hyperthyroidism control 0·44 (0·20, 0·94) 0·033 0·45 (0·21, 0·96) 0·040 
 Thyroidectomy 0·35 (0·09, 1·43) 0·144 0·19 (0·03, 1·40) 0·103 
Supplementary Table 8: Multivariable analysis for MACE  
HR (95% CI) are obtained from multivariable Cox proportional hazard regression models. Model 1, all patients, n=4189; Model 2, patients with 
thyroid function tests, n=2969; Serial thyroid hormones and treatment were set as time-dependent covariates. Patients contributed person-years 
of treatment from diagnosis to radioiodine treatment or thyroidectomy (ATD), following radioiodine to control of hyperthyroidism (RAI without 
hyperthyroidism control), following radioiodine and control of hyperthyroidism (RAI with hyperthyroidism control), and following thyroidectomy 
(thyroidectomy).   a, HR per 5-year increase in age; b, HR per 5-year increase in diagnosis year, c, HR per 10 IU/L increase in TRAb 
concentration, d, HR per 10 pmol/L increase in FT4 concentration 
